Alvarez Ezequiel, Campos-Toimil Manuel, Justiniano-Basaran Hélène, Lugnier Claire, Orallo Francisco
Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, Campus Universitario Sur, Santiago de Compostela (A Coruña), E-15782, Spain.
Br J Pharmacol. 2006 Feb;147(3):269-80. doi: 10.1038/sj.bjp.0706507.
This study investigated several mechanisms involved in the vasorelaxant effects of (-)-epigallocatechin-3-gallate (EGCG). EGCG (1 microM-1 mM) concentration dependently relaxed, after a transient increase in tension, contractions induced by noradrenaline (NA, 1 microM), high extracellular KCl (60 mM), or phorbol 12-myristate 13-acetate (PMA, 1 microM) in intact rat aortic rings. In a Ca2+ -free solution, EGCG (1 microM-1 mM) relaxed 1 microM PMA-induced contractions, without previous transient contraction. However, EGCG (1 microM-1 mM) did not affect the 1 microM okadaic acid-induced contractions. Removal of endothelium and/or pretreatment with glibenclamide (10 microM), tetraethylammonium (2 mM) or charybdotoxin (100 nM) plus apamin (500 nM) did not modify the vasorelaxant effects of EGCG. In addition, EGCG noncompetitively antagonized the contractions induced by NA (in 1.5 mM Ca2+ -containing solution) and Ca2+ (in depolarizing Ca2+ -free high KCl 60 mM solution). In rat aortic smooth muscle cells (RASMC), EGCG (100 microM) reduced increases in cytosolic free Ca2+ concentration ([Ca2+]i) induced by angiotensin II (ANG II, 100 nM) and KCl (60 mM) in 1.5 mM CaCl2 -containing solution and by ANG II (100 nM) in the absence of extracellular Ca2+. In RASMC, EGCG (100 microM) did not modify basal generation of cAMP or cGMP, but significantly reversed the inhibitory effects of NA (1 microM) and high KCl (60 mM) on cAMP and cGMP production. EGCG inhibited the enzymatic activity of all the cyclic nucleotide PDE isoenzymes present in vascular tissue, being more effective on PDE2 (IC50 approximately 17) and on PDE1 (IC50 approximately 25). Our results suggest that the vasorelaxant effects of EGCG in rat aorta are mediated, at least in part, by an inhibition of PDE activity, and the subsequent increase in cyclic nucleotide levels in RASMC, which, in turn, can reduce agonist- or high KCl concentration-induced increases in [Ca2+]i.
本研究调查了(-)-表没食子儿茶素-3-没食子酸酯(EGCG)血管舒张作用的几种机制。在完整的大鼠主动脉环中,EGCG(1微摩尔/升至1毫摩尔/升)在张力短暂升高后,能浓度依赖性地舒张由去甲肾上腺素(NA,1微摩尔/升)、高细胞外氯化钾(60毫摩尔/升)或佛波醇12-肉豆蔻酸酯13-乙酸酯(PMA,1微摩尔/升)诱导的收缩。在无钙溶液中,EGCG(1微摩尔/升至1毫摩尔/升)能舒张1微摩尔/升PMA诱导的收缩,且无先前的短暂收缩。然而,EGCG(1微摩尔/升至1毫摩尔/升)对1微摩尔/升冈田酸诱导的收缩无影响。去除内皮和/或用格列本脲(10微摩尔/升)、四乙铵(2毫摩尔/升)或蝎毒素(100纳摩尔/升)加蜂毒明肽(500纳摩尔/升)预处理,均不改变EGCG的血管舒张作用。此外,EGCG非竞争性拮抗NA(在含1.5毫摩尔/升钙的溶液中)和钙(在去极化的无钙高氯化钾60毫摩尔/升溶液中)诱导的收缩。在大鼠主动脉平滑肌细胞(RASMC)中,EGCG(100微摩尔/升)可降低在含1.5毫摩尔/升氯化钙的溶液中由血管紧张素II(ANG II,100纳摩尔/升)和氯化钾(60毫摩尔/升)以及在无细胞外钙时由ANG II(100纳摩尔/升)诱导的胞质游离钙浓度([Ca2+]i)升高。在RASMC中,EGCG(100微摩尔/升)不改变环磷酸腺苷(cAMP)或环磷酸鸟苷(cGMP)的基础生成,但能显著逆转NA(1微摩尔/升)和高氯化钾(60毫摩尔/升)对cAMP和cGMP生成的抑制作用。EGCG抑制血管组织中所有环核苷酸磷酸二酯酶同工酶的酶活性,对磷酸二酯酶2(IC50约为17)和磷酸二酯酶1(IC50约为25)的作用更有效。我们的结果表明,EGCG在大鼠主动脉中的血管舒张作用至少部分是由抑制磷酸二酯酶活性介导的,随后RASMC中环核苷酸水平升高,进而可减少激动剂或高氯化钾浓度诱导的[Ca2+]i升高。